Matica Biotechnology Inc., a CDMO specializing in viral vector development and manufacturing, has signed a Letter of Intent (LOI) with KaliVir Immunotherapeutics, a U.S.-based clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapies.
 
KaliVir is at the forefront of developing novel cancer therapies using its proprietary Vaccinia Enhanced Template (VET) platform, which allows for the expression and systemic delivery of multiple therapeutic transgenes. KaliVir’s lead clinical candidate, VET3-TGI, expresses interleukin-12 and a TGFbeta inhibitor.
 
Under this new partnership, Matica Bio will utilize its proprietary cell line, MatiMax, to explore a new manufacturing process for KaliVir’s oncolytic virus product.
 
Helena Chaye, CEO of KaliVir, stated, “Our collaboration with Matica Bio allows us to accelerate the development of our oncolytic virus therapies. This agreement is expected to expand our strategic partnership across all phases of product development.”
 
“The development of production processes for viral vectors is crucial for the stable production of high-quality therapeutics. Through this agreement, we aim to leverage our high-performance MatiMax cell line and CGT manufacturing expertise to actively support KaliVir’s oncolytic virus program,” said Paul Kim, CEO of Matica Bio.